4D Molecular Therapeutics, Inc.
FDMT· Nasdaq· Biological Products, (No Diagnostic Substances)
- Market cap
- –
- P/FCF
- –
- EV/Sales
- –
- FCF margin
- -128.6%
- ROIC, 5 yr avg
- –
- Revenue, 5 yr CAGR
- +44.8%
We record prices for the companies we cover; FDMT is not one of them yet.
Company statistics
Profile · FY2025
- Market cap
- –
- Enterprise value
- –
- Diluted shares
- 57.9M
- Revenue
- $85.2M
- Free cash flow
- -$109.6M
- Owner earnings
- -$131.6M
Valuation · FY2025
- P/E
- –
- P/FCF
- –
- P/Owner earnings
- –
- EV/Sales
- –
- EV/FCF
- –
- P/B
- –
Margins · FY2025
- Gross
- –
- Operating
- -187.2%
- Net
- -164.4%
- Free cash flow
- -128.6%
- Owner earnings
- -154.5%
- Stock pay
- 25.8%
Returns
- ROIC, FY2025
- –
- ROIC, 5 yr avg
- –
- ROE, FY2025
- -27.7%
- ROE, 5 yr avg
- -32.2%
Growth (CAGR)
- Revenue, 3 yr
- 200.9%
- Revenue, 5 yr
- 44.8%
- Revenue, 6 yr
- 51.8%
- Diluted EPS, 3 yr
- –
- Diluted EPS, 5 yr
- –
- Diluted EPS, 6 yr
- –
- Free cash flow, 3 yr
- –
- Free cash flow, 5 yr
- –
- Free cash flow, 6 yr
- –
Financial health · FY2025
- Cash and investments
- $402.7M
- Total debt
- –
- Net cash
- –
- Debt/Equity
- –
- Debt/FCF
- –
Shareholder returns · FY2025
- Dividend yield
- –
- Payout ratio
- –
- Buyback yield
- –
- Shareholder yield
- –
- Share count, 5 yr
- –
Financials: ten years from the 10-Ks
Revenue
$85.2M
+51.8% a year over 6 years
FY2019FY2025
Margins
Operating-187.2%Net-164.4%
FY2025
FY2019FY2025
Free cash flow and owner earnings
Free cash flow-$109.6MOwner earnings-$131.6M
FY2025
FY2019FY2025
Diluted shares
57.9M
+108.9% over 6 years, net dilution
FY2019FY2025
Every figure, year by year
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| The business | |||||||
| Revenue | $7.0M | $13.4M | $18.0M | $3.1M | $20.7M | $37.0K | $85.2M |
| Revenue growth | – | 92.0% | 35.0% | -82.7% | 562.3% | -99.8% | 230194.6% |
| Gross margin | – | – | – | – | – | – | – |
| Operating margin | -729.4% | -424.0% | -395.5% | -3516.5% | -544.6% | -507678.4% | -187.2% |
| Net income | -$49.3M | -$56.7M | -$71.3M | -$107.5M | -$100.8M | -$160.9M | -$140.1M |
| Net margin | -708.4% | -424.3% | -395.4% | -3435.4% | -486.6% | -434778.4% | -164.4% |
| Diluted EPS | – | – | $-2.57 | $-3.32 | $-2.58 | $-2.98 | $-2.42 |
| Return on invested capital? | – | – | – | – | – | – | – |
| Cash | |||||||
| Operating cash flow | -$36.7M | -$50.9M | -$69.1M | -$86.7M | -$75.8M | -$134.6M | -$109.1M |
| Capital expenditure | $3.2M | $1.0M | $9.1M | $11.5M | $2.8M | $3.8M | $536.0K |
| Free cash flow | -$39.9M | -$51.9M | -$78.2M | -$98.2M | -$78.6M | -$138.4M | -$109.6M |
| Stock-based compensation | $3.5M | $5.0M | $13.8M | $17.1M | $19.7M | $26.1M | $22.0M |
| Owner earnings? | -$43.5M | -$56.9M | -$92.0M | -$115.3M | -$98.2M | -$164.5M | -$131.6M |
| Free cash flow per share | – | – | $-2.82 | $-3.04 | $-2.01 | $-2.57 | $-1.89 |
| Capital allocation | |||||||
| Dividends paid | – | – | – | – | – | – | – |
| Share repurchases | – | – | – | – | – | – | – |
| Diluted shares | – | – | 27.7M | 32.4M | 39.1M | 53.9M | 57.9M |
| Share count change? | – | – | – | 16.7% | 21.0% | 37.9% | 7.4% |
| Balance sheet | |||||||
| Cash and equivalents | $49.7M | $276.7M | $153.0M | $52.4M | $249.1M | $149.3M | $60.2M |
| Short-term investments | – | $0 | $94.8M | $161.2M | $39.1M | $275.5M | $342.4M |
| Total debt | – | – | – | – | – | – | – |
| Net debt | – | – | – | – | – | – | – |
| Shareholders' equity | -$73.0M | $256.4M | $319.1M | $231.3M | $307.8M | $510.6M | $505.7M |
Latest filings
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Earnings release |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-05-07 | 8-K | Earnings release |
| 2026-04-28 | DEF 14A | Proxy statement |
| 2026-03-18 | 10-K | Annual report |
| 2026-03-18 | 8-K | Earnings release |
| 2026-01-07 | 8-K | Earnings release |
| 2025-11-10 | 10-Q | Quarterly report |
| 2025-11-10 | 8-K | Earnings release |
More from our coverage
- MSFTPlatforms8.4MicrosoftThe most entrenched software franchise in the enterprise, now spending its cash flow on AI capacity; a great business we would own with a margin of safety, not at any price.Base value $410.29
- NVDAAI infrastructure8.4NVIDIAThe best business in technology at the top of its cycle: the moat is CUDA as much as silicon, but today's margins are a peak, not a floor.Base value $104.32
- AAPLHardware7.6AppleOne of the highest-quality businesses in the world growing in the low single digits; the price usually assumes more growth than the numbers show.Base value $134.27
- GOOGLPlatforms7.4AlphabetSearch pays for everything, and AI is both its biggest threat and its biggest opportunity; the price has to allow for search being worth less than it was.Base value $209.60
- NOWSoftware7.4ServiceNowA rare enterprise platform still growing above 20% with high retention; the free cash flow is real but stock pay takes a large share of it.Base value $189.13
- ADBESoftware7.4AdobeSuperb margins and a shrinking share count, priced for decline; the question is whether AI makes Adobe's tools more valuable or makes them unnecessary.Base value $449.35
